Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab with or without chemotherapy for advanced penile cancer
ISRCTN95561634Phase 2Active, not recruiting
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of cemiplimab in penile squamous cell carcinoma (PSCC) (2 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Clinical benefit rate after cycle 4. Started Nov 2021; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ISRCTN95561634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95561634.